Novo’s Insulin Icodec: Hypoglycemia Events In Type 1 Diabetics Put Broad Indication At Risk

A US FDA advisory committee will consider whether the benefits of once-weekly insulin icodec outweigh the significantly higher rate of hypoglycemic episodes in patients with type 1 disease. The agency appears satisfied with safety and efficacy in type 2 diabetics.